Investigational Drug Information for BMS-986256
✉ Email this page to a colleague
What is the development status for investigational drug BMS-986256?
BMS-986256 is an investigational drug.
There have been 11 clinical trials for BMS-986256.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 30th 2021.
The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous, and [disabled in preview]. The leading clinical trial sponsors are Bristol-Myers Squibb and [disabled in preview].
Summary for BMS-986256
| US Patents | 0 |
| International Patents | 32 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-06-30) |
| Vendors | 25 |
Recent Clinical Trials for BMS-986256
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam | Bristol-Myers Squibb | Phase 1 |
| A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants | Bristol-Myers Squibb | Phase 1 |
| A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Bristol-Myers Squibb | Phase 2 |
Clinical Trial Summary for BMS-986256
Top disease conditions for BMS-986256
Top clinical trial sponsors for BMS-986256
US Patents for BMS-986256
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BMS-986256
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BMS-986256 | Argentina | AR108905 | 2036-06-29 | ⤷ Subscribe |
| BMS-986256 | Australia | AU2017287902 | 2036-06-29 | ⤷ Subscribe |
| BMS-986256 | Brazil | BR112018077119 | 2036-06-29 | ⤷ Subscribe |
| BMS-986256 | Canada | CA3029620 | 2036-06-29 | ⤷ Subscribe |
| BMS-986256 | Chile | CL2018003821 | 2036-06-29 | ⤷ Subscribe |
| BMS-986256 | China | CN109641895 | 2036-06-29 | ⤷ Subscribe |
| BMS-986256 | Colombia | CO2019000686 | 2036-06-29 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
